Event
Neuralink raises $650 million Series E to expand clinical trials and BCI development
Key points
- Neuralink closed a $650 million Series E funding round.
- Investors included ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, Sequoia Capital, Thrive Capital, and Vy Capital.
- Neuralink said the funding would support expanded access to its technology, clinical work, and further development of brain-computer interfaces.
Company context
Neuralink is a neurotechnology company developing implantable brain-computer interfaces for people with unmet medical needs, beginning with device control for people with paralysis. Its system combines the N1 Implant, external software, wireless communication, and the R1 surgical robot used to place ultra-fine electrode threads in the brain.
Context
- Company
- Neuralink
- Segment
- Healthcare
- Event type
- Funding
- Geography
- Fremont · United States